21 May 2020

The Brighton and Sussex University Hospitals and the John Radcliffe Hospital in Oxford in the UK have launched a global clinical trial to assess hydroxychloroquine for potentially preventing Covid-19. This trial is designed to investigate chloroquine and hydroxychloroquine in more than 40,000 healthcare workers across Europe, Africa, Asia and South America, according to BBC. These sites in the UK are the first of a planned 25 across the country.

Inovio Pharmaceuticals has reported promising data from the preclinical studies of its Covid-19 vaccine candidate, IN0-480, in mice and guinea pigs. The candidate was found to have generated ‘robust’ neutralising antibodies and T cell responses against SARS-CoV-2, the novel coronavirus that causes Covid-19.

India-based Strides Pharma Science has secured regulatory approval from the Drug Controller General of India to perform clinical trials of antiviral drug favipiravir as a potential Covid-19 treatment, according to Reuters. This makes Strides the second Indian company to trial the drug for Covid-19, following Glenmark Pharmaceuticals, which started Phase III trials of favipiravir earlier this month.

China-based CanSino Biologics has partnered with Precision NanoSystems in Canada to jointly develop a mRNA lipid nanoparticle vaccine against Covid-19. The collaboration will leverage PNI’s RNA vaccine platform, which comprises lipid nanoparticle delivery system and the NanoAssemblr manufacturing technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.